MedTrace Logo

Comparison of Telemedicine to Usual Care for HCV Management for Methadone-maintained Individuals

NCT02933970 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 602

Last updated 2024-12-20

Study results available
· View outcomes & findings →

Summary

To compare the effectiveness of a patient-centered, opiate agonist treatment (OAT)-integrated telemedicine-based approach for management and delivery of hepatitis C virus (HCV) treatment to persons with substance use disorders (PWSUD) versus usual care, which we anticipate in most cases will be referral to an offsite location for HCV management. The effectiveness will be expressed through the primary patient centered and clinical outcome, achievement of viral eradication, defined as undetectable HCV RNA 12 weeks post-treatment cessation.

Conditions

  • Hepatitis C

Interventions

OTHER

Telemedicine

Patients will be linked with the provider via two-way video-teleconferencing facilitated by an onsite OAT program staff member

Sponsors & Collaborators

  • Patient-Centered Outcomes Research Institute

    collaborator OTHER

  • Andrew Talal

    lead OTHER

Principal Investigators

  • Andrew H Talal, MD · SUNY Buffalo

Study Design

Allocation
RANDOMIZED
Purpose
HEALTH_SERVICES_RESEARCH
Masking
NONE
Model
CROSSOVER

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2017-02-28
Primary Completion
2020-10-01
Completion
2022-11-01

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02933970 on ClinicalTrials.gov